Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793664

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793664

Oral Proteins and Peptides

PUBLISHED:
PAGES: 278 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Oral Proteins and Peptides Market to Reach US$2.0 Billion by 2030

The global market for Oral Proteins and Peptides estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Calcitonin Drug Type, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$762.5 Million by the end of the analysis period. Growth in the Insulin Drug Type segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.6 Million While China is Forecast to Grow at 11.3% CAGR

The Oral Proteins and Peptides market in the U.S. is estimated at US$351.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$411.9 Million by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Oral Proteins and Peptides Market - Key Trends & Drivers Summarized

Why Has Oral Delivery of Proteins and Peptides Remained Technically Difficult?

Proteins and peptides are sensitive biological molecules with poor intrinsic stability in the digestive system. When administered orally, they face rapid degradation by gastric enzymes and harsh pH conditions, followed by limited intestinal absorption due to large molecular size and hydrophilicity. These barriers have historically limited oral use of therapeutic proteins, pushing most into parenteral routes. However, recent scientific progress is making oral delivery more plausible, driving new investment in peptide-based oral drug development.

The motivation behind oral delivery is strong, particularly for long-term treatments like diabetes, growth disorders, and hormonal deficiencies. Patients prefer oral therapies over injections for convenience, comfort, and reduced risk of injection-related complications. Hence, the pharmaceutical industry is actively working on approaches to stabilize peptide structures and promote mucosal transport for systemic absorption.

What Formulation Techniques Are Enabling Systemic Uptake via the GI Tract?

Several formulation strategies are under active development to enable oral delivery of peptides and proteins. Use of enteric-coated capsules and enzyme inhibitors helps protect the drug until it reaches the intestine. Absorption enhancers such as medium-chain fatty acids and bile salts are employed to loosen tight junctions in the intestinal lining, temporarily increasing permeability. Carrier systems like nanoparticles, self-emulsifying drug delivery systems (SEDDS), and lipid-based formulations are designed to improve drug solubility and stability.

Technologies such as permeation-enhancing microcontainers, mucoadhesive films, and transcellular transporters are being refined to achieve consistent and safe absorption. Structural modification of peptides, including cyclization and D-amino acid substitution, improves resistance to enzymatic cleavage without affecting biological activity. These methods are allowing more peptide drugs to achieve bioavailability levels sufficient for therapeutic effect.

Which Therapies Are Leading in Development and Where Is Innovation Concentrated?

Diabetes and metabolic disorders are the leading therapeutic segments for oral peptide development. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes, is the most notable commercial success, marking a breakthrough in this space. Similar efforts are targeting oral formulations of insulin, parathyroid hormone, and calcitonin for osteoporosis and thyroid-related disorders.

Biopharmaceutical companies are also exploring oral delivery of peptide-based immunotherapies and anti-inflammatory agents for conditions such as rheumatoid arthritis and ulcerative colitis. North America and select European countries are leading innovation due to strong R&D infrastructure and regulatory engagement. Emerging economies are watching closely for cost-effective formulations to broaden access.

Growth in the Oral Proteins and Peptides market is driven by several factors…

Growth in the oral proteins and peptides market is driven by factors such as increasing demand for convenient alternatives to injectable biologics, progress in drug stabilization techniques, and growing therapeutic use of peptides in chronic diseases. Rising adoption of GLP-1 analogs and other metabolic treatments is fueling commercial interest in oral peptide delivery platforms.

Advancements in bioavailability enhancers, protective coatings, and intestinal absorption models are supporting wider application of peptide therapies in outpatient settings. Expansion of clinical pipelines, coupled with favorable patient preferences and emerging regulatory approvals, is creating a strong foundation for long-term market growth. Strategic partnerships between biotech firms and delivery technology companies are further accelerating the pace of innovation in this evolving field.

SCOPE OF STUDY:

The report analyzes the Oral Proteins and Peptides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type, Plecanatide Drug Type); Application (Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application, Hormonal Disorders Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37601

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Proteins and Peptides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Non-Invasive Biologic Delivery Spurs Innovation in Oral Protein and Peptide Formulations
    • Advancements in Permeation Enhancers Strengthen Business Case for Gastrointestinal Absorption Technologies
    • Surge in Oral GLP-1 Receptor Agonist Development Throws the Spotlight on Diabetes and Obesity Therapies
    • Increasing Focus on Enzyme and Hormone Replacement Expands Addressable Market for Oral Biologics
    • Progress in Nanotechnology and Carrier Systems Enhances Stability and Bioavailability of Oral Peptides
    • Use of Enteric Coating and Mucoadhesive Polymers Propels Controlled Release Formulation Development
    • Rising Investment in Oral Immunotherapy Supports New Pathways for Allergy and Autoimmune Treatment
    • Expansion of Biopharma Pipelines in Peptides Drives Demand for Alternative Drug Delivery Routes
    • Growing Application in Oncology and Rare Diseases Opens High-Value Market Segments for Oral Peptides
    • Technological Advances in Oral Nanocarriers Enhance Gastrointestinal Uptake and Therapeutic Impact
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Proteins and Peptides Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Calcitonin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Insulin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Linaclotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Octreotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Plecanatide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bone Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Gastric & Digestive Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hormonal Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CHINA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • INDIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!